Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Anadrol and Ezetimibe Interaction: Avoid | Peptide Database

Compound Profiles Anadrol Oral Anabolic Steroid | Extreme Mass & Strength Oxymetholone exerts its effects primarily through binding to the androgen receptor (AR) to promote protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it ca

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Anadrol

Oral Anabolic Steroid | Extreme Mass & Strength

Oxymetholone exerts its effects primarily through binding to the androgen receptor (AR) to promote protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme.

Ezetimibe

Cholesterol Absorption Inhibitor | Lipid Management On Cycle

Ezetimibe selectively inhibits the NPC1L1 transporter protein located on the luminal surface of enterocytes in the jejunum of the small intestine. NPC1L1 is the critical gateway for intestinal cholesterol absorption, responsible for uptaking both dietary cholesterol and the much larger pool of biliary cholesterol that is recirculated through the enterohepatic cycle.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Anadrol with Ezetimibe?

Combining Anadrol with Ezetimibe is not recommended. Both Anadrol and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anadrol and Ezetimibe safe together?

This combination carries significant risk. Both Anadrol and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anadrol and Ezetimibe?

Both Anadrol and Ezetimibe carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anadrol and Ezetimibe?

Anadrol has a half-life of ~8-9 hours and Ezetimibe has a half-life of ~22 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training. Sustained GH patterns may accelerate muscle repair between exercise sessions. GH optimization helps maintain muscle during caloric restriction or aging. Growth hormone promotes lipolysis while supporting lean tissue maintenance. Enhanced GH patterns may improve glucose and fat utilization. Evening GH peaks align with deeper, more restorative sleep patterns. Sustained GH elevation supports skin elasticity and connective tissue health. Growth hormone supports tissue repair and recovery from exercise or injury. Enhanced collagen synthesis supports joint and connective tissue integrity.

Source: peptide-db.com ↗

Community Research

Join others researching VIP — share findings, ask questions, and learn from real experiences Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide belonging to the glucagon/secretin superfamily. It is produced in many tissues including the gut, pancreas, and brain. VIP has potent vasodilatory, anti-inflammatory, and immunomodulatory effects. It binds to VPAC1 and VPAC2 receptors, triggering cAMP-mediated signaling cascades. Research shows therapeutic potential for pulmonary hypertension, diabetes, neurological disorders, and autoimmune conditions. VIP binds to VPAC1 and VPAC2 G protein-coupled receptors, activating adenylyl cyclase and increasing intracellular cAMP and PKA activity. This triggers phosphorylation of CREB and other transcription factors. VIP causes vasodilation through NO-dependent and independent mechanisms, stimulates intestinal secretion, relaxes smooth muscle, inhibits gastric acid secretion, and has positive inotropic/chronotropic cardiac effects.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Currently in experimental stages. The original 2017 mouse study used 5 mg/kg intraperitoneally, three times on alternate days. For a 60kg human, this translates to approximately 25 mg per dose. Self-experimenters have reported using subcutaneous injection. Storage at -20°C required due to peptide stability concerns. Standard senolytic protocol 25-33 mg 3 doses, every other day (6 days total) SubQ or IV Mouse study equivalent 5 mg/kg (translates to ~25 mg for 60kg human) 3 doses on alternate days IP (original study)

Source: peptide-db.com ↗
Side effects

Common Side Effects

Liver stress and enzyme elevation (ALT, AST) due to 17-alpha alkylated steroidal structure Testosterone suppression (dose- and duration-dependent, expected in all users) Joint dryness and discomfort (related to reduced estrogenic activity and potential drying effect) Hair shedding (consistent with androgenic activity from the DHT-derived structure; may or may not be reversible) Lipid disruption (HDL suppression, LDL elevation) Reduced libido and mood changes secondary to hormonal suppression Mild headaches, particularly during the first week

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides